Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Trop Med Hyg
Glavni autori: Martinez, Luis Javier, Lin, Leyi, Blaylock, Jason M., Lyons, Arthur G., Bauer, Kristen M., De La Barrera, Rafael, Simmons, Monika, Jarman, Richard G., Currier, Jeffrey R., Friberg, Heather, Danko, Janine R., Teneza-Mora, Nimfa C., Putnak, J. Robert, Eckels, Kenneth H., Thomas, Stephen J.
Format: Artigo
Jezik:Inglês
Izdano: The American Society of Tropical Medicine and Hygiene 2015
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559679/
https://ncbi.nlm.nih.gov/pubmed/26149862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4269/ajtmh.14-0819
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items